NASDAQ:AVDL - Avadel Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $7.11 -0.01 (-0.14 %) (As of 07/15/2018 04:00 PM ET)Previous Close$7.11Today's Range$7.08 - $7.2752-Week Range$5.60 - $11.93Volume159,889 shsAverage Volume429,072 shsMarket Capitalization$261.26 millionP/E Ratio22.94Dividend YieldN/ABeta1.73 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria. The company owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. Its product candidates also comprise REST-ON, which is in Phase III clinical trial for the treatment of daytime sleepiness and cataplexy in patients suffering from narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. The company was founded in 1990 and is headquartered in Dublin, Ireland. Receive AVDL News and Ratings via Email Sign-up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:AVDL CUSIPN/A Webwww.avadel.com Phone636-449-1830 Debt Debt-to-Equity Ratio1.28 Current Ratio2.66 Quick Ratio2.59 Price-To-Earnings Trailing P/E Ratio22.94 Forward P/E Ratio-4.59 P/E GrowthN/A Sales & Book Value Annual Sales$172.74 million Price / Sales1.51 Cash Flow$0.4477 per share Price / Cash15.88 Book Value$2.18 per share Price / Book3.26 Profitability EPS (Most Recent Fiscal Year)$0.31 Net Income$68.27 million Net Margins18.96% Return on Equity-13.95% Return on Assets-4.22% Miscellaneous Employees180 Outstanding Shares36,740,000Market Cap$261.26 Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions What is Avadel Pharmaceuticals' stock symbol? Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL." How will Avadel Pharmaceuticals' stock buyback program work? Avadel Pharmaceuticals announced that its board has approved a share repurchase program on Wednesday, March 28th 2018, which authorizes the company to repurchase $7,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 2.7% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's management believes its stock is undervalued. How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals PLC (NASDAQ:AVDL) posted its quarterly earnings data on Wednesday, May, 2nd. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.08. The firm earned $33.29 million during the quarter, compared to the consensus estimate of $29.60 million. Avadel Pharmaceuticals had a net margin of 18.96% and a negative return on equity of 13.95%. View Avadel Pharmaceuticals' Earnings History. When is Avadel Pharmaceuticals' next earnings date? Avadel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Avadel Pharmaceuticals. What price target have analysts set for AVDL? 3 equities research analysts have issued 1 year price objectives for Avadel Pharmaceuticals' shares. Their predictions range from $14.00 to $30.00. On average, they anticipate Avadel Pharmaceuticals' stock price to reach $22.6667 in the next twelve months. This suggests a possible upside of 218.8% from the stock's current price. View Analyst Ratings for Avadel Pharmaceuticals. What is the consensus analysts' recommendation for Avadel Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting Avadel Pharmaceuticals? Avadel Pharmaceuticals saw a decrease in short interest during the month of June. As of June 29th, there was short interest totalling 2,282,363 shares, a decrease of 31.1% from the June 15th total of 3,310,728 shares. Based on an average daily trading volume, of 561,837 shares, the days-to-cover ratio is presently 4.1 days. View Avadel Pharmaceuticals' Current Options Chain. Who are some of Avadel Pharmaceuticals' key competitors? Some companies that are related to Avadel Pharmaceuticals include OptiNose (OPTN), Vanda Pharmaceuticals (VNDA), Flexion Therapeutics (FLXN), Omeros (OMER), Dynavax Technologies (DVAX), Karyopharm Therapeutics (KPTI), MacroGenics (MGNX), Epizyme (EPZM), CytomX Therapeutics (CTMX), Amarin (AMRN), Rhythm Pharmaceuticals (RYTM), Assembly Biosciences (ASMB), ANI Pharmaceuticals Inc Common Stock (ANIP), Homology Medicines (FIXX) and Inflarx (IFRX). Who are Avadel Pharmaceuticals' key executives? Avadel Pharmaceuticals' management team includes the folowing people: Mr. Michael S. Anderson, CEO & Director (Age 69)Mr. Michael F. Kanan, Sr. VP & CFO (Age 55)Mr. Gregory J. Divis, Exec. VP & COO (Age 53)Mr. Phillandas T. Thompson, Sr. VP, Gen. Counsel & Corp. Sec. (Age 44)Dr. David Monteith, VP of R&D (Age 54) Has Avadel Pharmaceuticals been receiving favorable news coverage? News stories about AVDL stock have been trending somewhat positive on Sunday, Accern Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Avadel Pharmaceuticals earned a media sentiment score of 0.19 on Accern's scale. They also gave media stories about the company an impact score of 45.59 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term. How do I buy shares of Avadel Pharmaceuticals? Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Avadel Pharmaceuticals' stock price today? One share of AVDL stock can currently be purchased for approximately $7.11. How big of a company is Avadel Pharmaceuticals? Avadel Pharmaceuticals has a market capitalization of $261.26 million and generates $172.74 million in revenue each year. The company earns $68.27 million in net income (profit) each year or $0.31 on an earnings per share basis. Avadel Pharmaceuticals employs 180 workers across the globe. How can I contact Avadel Pharmaceuticals? Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 636-449-1830 or via email at [email protected] MarketBeat Community Rating for Avadel Pharmaceuticals (NASDAQ AVDL)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 188 (Vote Outperform)Underperform Votes: 153 (Vote Underperform)Total Votes: 341MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVDL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: Should I follow buy, hold and sell recommendations?